Recombinant cancer therapeutic cytokine
AssigneeVirginia Commonwealth University
InventorsPaul B. Fisher, Praveen Bhoopathi, Swadesh K. Das, Luni Emdad, Devanand Sarkar, Upneet Sokhi
Life of this patent
Estimating the term…
Abstract
Recombinant therapeutic cytokines (“therakines”) for the treatment of cancer are provided. The recombinant therakines include a truncated region of MDA-7/TL-24 (“M4”) not normally found in nature that has anti-cancer activity and a secretory signal which causes secretion of the therakine from plasmid/virus transduced normal and cancer cells and interaction of the therakine to MDA-7/IL-24 receptors on adjacent, neighboring and distant cancer cells. Therakine interaction results in bystander killing of the target cancer cell as well as adjacent, neighboring and distant cancer cells.
Claims34
A recombinant cytokine comprising
- a fragment of MDA-7/IL-24 that i) has antitumor activity and ii) interacts with MDA-7/IL-24 receptors on the surface of cancer cells;
- and
- a secretory leader sequence.
A nucleic acid sequence encoding a recombinant cytokine comprising a fragment of MDA-7/IL-24 that i) has antitumor activity and ii) interacts with MDA-7/IL-24 receptors on the surface of cancer cells;
- and a secretory leader sequence.
A recombinant vector comprising a nucleic acid sequence encoding a recombinant cytokine comprising
- a fragment of MDA-7/IL-24 that i) has antitumor activity and ii) interacts with MDA-7/IL-24 receptors on the surface of cancer cells;
- and
- a secretory leader sequence, wherein said nucleic acid sequence is operably linked to a promoter.
A nanoparticle comprising a nucleic acid sequence encoding a recombinant cytokine comprising a fragment of MDA-7/IL-24 that 1) has antitumor activity and ii) interacts with MDA-7/IL-24 receptors on the surface of cancer cells;
- and a secretory leader sequence, wherein said nucleic acid sequence is operably linked to a promoter.
A method of treating or preventing cancer and/or cancer metastasis in a subject in need thereof, comprising
- administering to said subject a recombinant cytokine comprising a fragment of MDA-7/IL-24 that i) has antitumor activity and ii) interacts with MDA-7/IL-24 receptors on the surface of cancer cells;
- and a secretory leader sequence.
A recombinant cDNA comprising the nucleotide sequence set forth as SEQ ID NO:
- 2, wherein said recombinant cDNA does not encode full length MDA-7/IL-24.
An isolated recombinant cytokine comprising a fragment of MDA-7/IL-24 that i) has antitumor activity and ii) interacts with MDA-7/IL-24 receptors on the surface of cancer cells.
Dependencies are inferred from the claim text.